Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesNatera Inc

Natera Inc

Healthcare Diagnostics & Research
PortfolioPortfolio WatchlistWatchlist
Company price
387.365 USD 8.45 ( 2.23%)
Last update at 2026-11-03T20:54:00Z
VOLUME
2746098
Market Cap
50562.90M

Momentum Score

…

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in Januar

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
382.10
Low
398.03
High
52 Week Price Range
157.43
Low
351.78
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
378.92
Dividend Yield
-
Revenue TTM
2707.08M
Revenue Per Share
19.32
Gross Profit TTM
1765.83M
Debt / Equity
0.13
ROE
-12.54%
Net Debt
-861.76M
ROCE
-12.77%
Diluted EPS TTM
-1.33

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -268.09M -189.73M -434.53M -546.82M -471.10M
Net income -208.16M -190.43M -434.80M -547.80M -471.72M
Selling general administrative 1177.26M 841.31M 618.31M 588.59M 511.03M
Gross profit 1495.49M 1023.16M 492.74M 363.97M 307.07M
Reconciled depreciation 43.48M 30.97M 24.10M 16.70M 11.25M
Ebit -264.02M -179.05M -421.89M -541.04M -468.17M
Ebitda -220.54M -148.08M -383.28M -537.50M -462.79M
Depreciation and amortization 43.48M 30.97M 38.62M 3.54M 5.38M
Operating income -309.91M -222.29M -446.25M -541.04M -468.17M
Other operating expenses 2616.02M 1919.20M 1528.82M 1361.26M 1093.66M
Interest expense 4.07M 10.69M 12.64M 9.32M 8.30M
Tax provision -59.93M 0.69M 0.27M 0.98M 0.62M
Interest income 45.89M 43.25M 24.35M 3.54M 5.38M
Net interest income 41.82M 32.56M 11.71M -5.78M -8.30M
Income tax expense -59.93M 0.69M 0.27M 0.98M 0.62M
Total revenue 2306.11M 1696.91M 1082.57M 820.22M 625.49M
Total operating expenses 1805.40M 1245.45M 938.99M 905.01M 775.24M
Cost of revenue 810.63M 673.75M 589.83M 456.26M 318.42M
Total other income expense net 41.82M 32.56M 11.71M -5.78M -2.92M
Net income from continuing ops -208.16M -190.43M -434.80M -547.80M -471.72M
Net income applicable to common shares - - - -547.80M -471.72M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 2508.04M 1660.73M 1457.12M 1394.47M 1236.49M
Intangible assets 373.71M 10.93M - - -
Other current assets 55.83M 48.63M 60.52M 33.63M 29.64M
Total liab 795.62M 465.31M 691.80M 688.73M 583.18M
Total stockholder equity 1712.41M 1195.42M 765.33M 705.74M 653.30M
Other current liab 287.26M 194.42M 183.64M 188.22M 134.29M
Common stock 0.01M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.01M 0.01M 0.01M 0.01M 0.01M
Retained earnings -2776.02M -2567.86M -2377.44M -1942.63M -1394.84M
Other liab - - - 20.00M 22.80M
Good will 141.07M 0.00M - - -
Other assets - - - 18.33M 18.82M
Cash 1076.14M 945.59M 642.10M 466.00M 84.39M
Total current liabilities 441.23M 344.05M 307.27M 310.50M 218.96M
Current deferred revenue 24.91M 19.75M 16.61M 10.78M 7.40M
Net debt -861.76M -758.47M -200.10M -27.43M 307.10M
Short term debt 95.90M 90.53M 92.02M 80.35M 50.05M
Short long term debt 80.32M 80.36M 80.40M 80.35M 50.05M
Short long term debt total 214.38M 187.12M 441.99M 438.58M 391.48M
Other stockholder equity 4488.68M 3763.61M 3145.84M 2664.73M 2050.42M
Property plant equipment - - - 92.45M 65.52M
Total current assets 1496.94M 1375.82M 1258.55M 1211.82M 1093.14M
Net tangible assets - - - 705.74M 653.30M
Short term investments 0.00M 22.69M 236.88M 432.30M 829.90M
Net receivables 296.53M 314.17M 278.29M 244.38M 122.07M
Long term debt - - 282.94M 281.65M 280.39M
Inventory 68.44M 44.74M 40.76M 35.41M 26.91M
Accounts payable 33.16M 34.92M 15.00M 31.15M 27.21M
Accumulated other comprehensive income -0.26M -0.34M -3.08M -16.36M -2.29M
Common stock total equity - - - 0.01M 0.01M
Retained earnings total equity - - - -1942.63M -1394.84M
Non currrent assets other 36.90M 36.72M 15.40M 18.33M 18.82M
Non current assets total 1011.10M 284.92M 198.58M 182.66M 143.35M
Capital lease obligations 134.05M 106.76M 78.65M 76.58M 66.79M
Long term debt total - - - 281.65M 280.39M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 23.00M 137.62M 168.50M 378.04M -155.60M
Change to liabilities - - - 56.18M 62.47M
Total cashflows from investing activities -132.21M 137.62M 168.50M 330.34M -205.19M
Net borrowings 0.00M -0.08M 0.00M 30.00M 30.00M
Total cash from financing activities 47.46M 30.20M 254.46M 482.64M 576.19M
Change to operating activities - - - 40.14M 29.77M
Net income -208.16M -190.43M -434.80M -547.80M -471.72M
Change in cash 130.55M 303.49M 176.00M 381.48M 35.76M
Begin period cash flow 945.59M 642.10M 466.09M 84.61M 48.85M
End period cash flow 1076.14M 945.59M 642.10M 466.09M 84.61M
Total cash from operating activities 215.30M 135.66M -246.96M -431.50M -335.24M
Issuance of capital stock 0.00M 0.00M 235.44M 433.19M 550.82M
Depreciation 43.48M 30.97M 24.10M 16.70M 11.25M
Other cashflows from investing activities 6.98M -10.49M - - -8.56M
Change to inventory -20.87M -3.98M -5.35M -8.26M -7.51M
Change to account receivables 20.75M -35.88M -33.90M -124.08M -43.35M
Sale purchase of stock - 17.30M 15.13M 13.04M 13.55M
Other cashflows from financing activities - 30.29M 19.02M 36.41M 11.82M
Change to netincome - - - 164.11M 151.24M
Capital expenditures 106.19M 66.42M 39.20M 47.70M 41.03M
Change receivables - - - -124.08M -43.35M
Cash flows other operating - - - 5.55M -46.67M
Cash and cash equivalents changes - - - 381.48M 35.76M
Change in working capital 10.04M 2.14M -47.95M -84.68M -46.07M
Stock based compensation 354.40M 274.43M 191.81M 152.38M 115.22M
Other non cash items 15.53M 18.55M 19.89M 31.89M 48.48M
Free cash flow 109.11M 69.24M -286.15M -479.20M -376.27M

Peer Comparison*

Sector: Healthcare Industry: Diagnostics & Research

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NTRA
Natera Inc		 8.45
2.23%		 387.37 - 5000.00 18.68 27.76 18.36 -26.80
TMO
Thermo Fisher Scientific Inc		 15.69
2.30%		 698.34 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 2.14
0.94%		 230.11 29.09 28.01 5.67 3.20 6.00 19.09
WUXIF
WuXi AppTec Co. Ltd		 -
-%		 23.25 22.29 17.95 1.53 5.98 8.39 14.30
WUXAY
WuXi AppTec Co. Ltd		 -0.81
3.50%		 22.35 23.28 18.73 1.51 6.24 8.39 14.30

Profile*

Natera Inc

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in Januar

13011 McCallen Pass, Austin, TX, United States, 78753

650 980 9190

https://www.natera.com

6135

Name Title Year Born
Dr. Matthew Rabinowitz Ph.D. Co-Founder & Exec. Chairman 1973
Mr. Steven Leonard Chapman CEO, Pres & Director 1979
Mr. Michael B. Brophy M.B.A. Chief Financial Officer 1980
Mr. Robert A. Schueren Chief Operating Officer 1962
Mr. Daniel Rabinowitz L.L.M., LL.M. Sec. & Chief Legal Officer 1969
Mr. Jonathan Sheena M.Eng. Co-Founder & Director 1973
Ms. Olesya A. Anisimova CPA Chief Accounting Officer NA
Mr. Rishi Kacker Chief Technology Officer NA
Mr. Eric A. Evans Chief Scientific Officer NA
Mr. Phil Grinnell VP of Sales NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

VNP
CAD 32.54
+24.44%
HUT
CAD 88.32
+14.81%
KEEL
CAD 3.05
+14.66%
MTY
CAD 36.63
+13.58%
CNL
CAD 15.98
+11.90%
MOON
CAD 4.72
-12.34%
EU
CAD 0.96
-8.57%
URE
CAD 1.02
-8.48%
AP-UN
CAD 3.71
-8.17%
HG
CAD 3.77
-8.05%

Equity Sectors*

  • Basic Materials

    -1.14%

  • Communication Services

    +0.65%

  • Consumer Cyclical

    +0.09%

  • Consumer Defensive

    -0.57%

  • Energy

    -0.15%

  • Financial Services

    +0.08%

  • Healthcare

    +2.18%

  • Industrials

    +2.04%

  • Real Estate

    -0.25%

  • Technology

    +1.02%

  • Utilities

    +0.66%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…